CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Ground breaking medical innovation, better patient outcomes, strong financial returns.
Brandon has been effective in raising successive funds that collectively cover the spectrum of life science venture investing. We also have a co-investment arrangement with our investors, providing significant capacity to support our advancing portfolio companies.
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom
